Reading Time: 3 minutes

 

– New data on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer to be presented in oral Proffered Paper session on Monday, Oct. 22 at 3:09 p.m. CEST

 

Eisai Inc. announced today the presentation of six abstracts featuring data and analyses on its cancer treatments at the European Society of Medical Oncology (ESMO) 2018 Congress taking place in Munich from October 19-23. The results to be presented highlight new data for the company’s oncology agents, lenvatinib (marketed as LENVIMA®) and eribulin (marketed as HALAVEN®) for approved and investigational uses, respectively.

Presentations of interest include:

  • An oral presentation on tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer.
  • Correlative analyses of serum biomarkers and efficiency outcomes for lenvatinib, everolimus and the combination of these two agents in patients with metastatic renal cell carcinoma.
  • A final analysis of serum biomarkers from a Phase III study of lenvatinib vs. sorafenib in unresectable hepatocellular carcinoma.
  • Early results of a Phase Ib/II study on the combination of eribulin and PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with HER2-negative, high hyaluronan metastatic breast cancer.

“Our data at ESMO include insights into the potential of lenvatinib and eribulin both as monotherapies and in combination with other agents across a variety of difficult-to-treat cancers,” said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group at Eisai. “As part of our human health care mission and dedication to patient access, we are committed to continually exploring ways to improve understanding of Eisai’s oncology treatments for the medical community and the patients impacted by these advanced cancers.”

This release discusses investigational compounds that are not Food and Drug Administration (FDA)-approved and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

The full list of Eisai presentations along with the time and location of each session is included below.

ABSTRACT NAME

SESSION (ALL TIMES ARE CEST)

Lenvatinib Abstracts (in collaboration with Merck)

Tumor growth rate and lenvatinib efficacy in 
radioiodine-refractory differentiated thyroid cancer

Presentation #1819O

Proffered Paper Session

Monday, October 22, 2018

3:09 p.m. – 3:33 p.m.

Location: Hall A1, Room 16

S. Leboulleux, MD

Correlative analyses of serum biomarkers and efficacy 
outcomes in the randomized, phase 2 trial of lenvatinib 
(LEN), everolimus (EVE) or LEN+EVE in patients with 
metastatic renal cell carcinoma

Presentation #76P

Poster Display Session

Saturday, October 20, 2018

12:30 p.m. – 1:30 p.m.

Location: Hall A3

C. H. Lee, MD, PhD

Final analysis of serum biomarkers in patients (pts) from 
the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) 
in unresectable hepatocellular carcinoma (uHCC) 
[REFLECT]

Presentation #59PD

Poster Discussion Session

Saturday, October 20, 2018

3:00 p.m. – 4:00 p.m.

Location: Hall B4, Room 19

R. Finn, MD

Eribulin Abstracts

Eribulin as first- or second-line chemotherapy for 
advanced or metastatic HER2-negative breast cancer: a 
real-world prospective study

Presentation #314P

Poster Display Session

Monday, October 22, 2018

12:45 p.m. – 1:45 p.m.

Location: Hall A3

M. Takahashi, MD

Early Results from an Open-label Phase 1b/2 Study of 
Eribulin Mesylate (EM) + Pegvorhyaluronidase Alfa 
(PEGPH20) Combination for the Treatment of Patients 
(Pts) with HER2-Negative, High-Hyaluronan (HA) 
Metastatic Breast Cancer (MBC)

Presentation #311P

Poster Display Session

Monday, October 22, 2018

12:45 p.m. – 1:45 p.m.

Location: Hall A3

M. Shum, MD

Economic Evaluation of Eribulin in the Treatment of Triple 
Negative Breast Cancer in the United Kingdom

Presentation #348P

Poster Display Session

Monday, October 22, 2018

12:45 p.m. – 1:45 p.m.

Location: Hall A3

J. Wex, MD, PhD

In March 2018, Eisai and Merck (known as MSD outside of the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.